Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Substituted phenethylamineamphetamine, mephedrone, MDMA +3 moreamphetamine, mephedrone, MDMA, 3-MMC, 4-CMC, methcathinone show less
3-CMC
3-chloromethcathinone
3-CMC (3-chloromethcathinone) — also known as clophedrone — is a synthetic stimulant of the substituted cathinone class. It is a positional isomer of 4-CMC and a halogenated structural analog of mephedrone. It floods the brain with dopamine, norepinephrine, and serotonin simultaneously,[1] producing the euphoria and sociability that define the experience.
3-CMC (3-chloromethcathinone) — also known as clophedrone — is a synthetic stimulant of the substituted cathinone class. It is a positional isomer of 4-CMC and a halogenated structural analog of mephedrone. 3-CMC is a monoamine releasing agent, producing its effects by flooding synapses with dopamine, norepinephrine, and serotonin.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Substituted phenethylamineamphetamine, mephedrone, MDMA +3 moreamphetamine, mephedrone, MDMA, 3-MMC, 4-CMC, methcathinone show less
No lab developed 3-CMC for medical use — it was first identified in a Swedish police seizure in September 2014.[2] It spread rapidly through European markets as a legal replacement after mephedrone and 4-CMC were controlled, accounting for over 63% of all NPS seizures in Europe by 2024.[3][4] It is now internationally controlled under Schedule II, and is increasingly found sold as MDMA.[3]
Subjective effects include euphoria, sociability, physical stimulation, emotional warmth, and compulsive urges to redose.[5] The experience is a short-lived stimulant-entactogen hybrid — a rush of warm energy and social ease that peaks quickly and drops sharply, leaving a craving that defines the compound's character. Anxiety, jaw tension, rapid heartbeat, and insomnia are common unwanted effects.
3-CMC carries high abuse liability, and fatalities where it was the sole identified substance confirm it can be lethal on its own.[6] The short duration drives compulsive redosing, escalating cardiovascular strain; combining it with GHB, MAOIs, or other serotonergic drugs multiplies the risk.[7] No controlled human studies exist — understanding rests on animal models, forensic case series, and one observational metabolism study.[3]
History[edit]
Discovery
3-CMC was not developed for clinical or therapeutic use. It was first identified in September 2014 after Swedish police seized a sample reported to the EMCDDA Early Warning System.[2] It emerged to fill the market gap left when mephedrone was controlled in 2010 and its successor 4-CMC in 2020.[4]
European market dominance
Its growth was exceptional. Seizures surged from 880 kg in 2020 to over 19,400 kg in 2022,[4] and by 2024 it represented over 63% of all new psychoactive substance seizures across Europe.[3] Production shifted from China to India after 2015, with the Netherlands intercepting 83% of imports.[4]
Regulatory response
The EU controlled 3-CMC in March 2022 after a risk assessment documented 10 confirmed deaths.[8] The WHO then recommended Schedule II placement in October 2023,[9][6] endorsed by the EU Council in March 2024.[10] The first confirmed US detection occurred in March 2024 in New York City.[11]
The name clophedrone comes from its structural relationship to chloro-ephedrone, though the term is rarely used outside regulatory documents. In European drug markets, 3-CMC is frequently sold as MDMA in pill or crystal form[4] — meaning many users do not know what they are actually taking.
Chemistry[edit]
Structural class
3-CMC belongs to the substituted cathinone family — a group of β-keto amphetamine-like compounds built on the phenethylamine scaffold. It carries a chlorine atom at the meta (3-) position of the phenyl ring, making it a positional isomer of 4-CMC (para-chloro) and a halogenated structural analog of 3-MMC (meta-methyl). Its molecular formula is C₁₀H₁₂ClNO (molecular weight 197.66 g/mol).
Physical properties
3-CMC degrades rapidly in biological samples. In whole blood stored at 4°C, the parent compound breaks down completely within approximately two months.[12] In a series of postmortem cases involving CMC isomers, only 44% showed detectable parent compound[12] — meaning death investigations may undercount 3-CMC's role.
Pharmacology[edit]
Mechanism of action
3-CMC forces dopamine, norepinephrine, and serotonin out of nerve terminals simultaneously[13][1] — unlike cocaine, which simply blocks reuptake. Its isomer 4-CMC has been directly tested at all three transporters with comparable potency to mephedrone,[14] and structural data suggest 3-CMC may be relatively more serotonergic than its para-chloro counterpart.[15]
Pharmacokinetics
No controlled human study has measured 3-CMC's half-life, bioavailability, or blood concentrations. The most informative data come from 16 regular users who self-administered the drug orally (100–150 mg) or intranasally (60–80 mg), identifying nine metabolites.[3] The dominant postmortem metabolite is dihydro-3-CMC, produced when the β-keto group is reduced by liver enzymes.[16]
By structural analogy to mephedrone, the liver enzyme CYP2D6 is the probable primary metaboliser.[17] People with genetically low CYP2D6 activity may clear the drug more slowly, increasing exposure and toxicity risk. inferred
Neuroscience[edit]
Where it acts
Dopamine release in the brain's mesolimbic pathway produces the euphoria and reinforcement that drive continued use.[13] Serotonin activity — predicted to be relatively pronounced in 3-CMC based on its meta-chloro structure[15] — likely underlies the emotional warmth and sociability users report.[5] Norepinephrine release drives the physical effects — elevated heart rate, blood pressure, and arousal documented in intoxication cases.[7]
Why it matters
The compulsive redosing pattern has a neurological explanation. As drug levels fall after 3-CMC's short peak, dopamine in the reward centre encodes intense craving independently of actual pleasure[18] — the compulsive redosing urge surges before the experience has fully ended.
In vitro studies show delayed toxicity in human neuronal cells through oxidative stress — damage that intensifies with prolonged exposure rather than appearing immediately.[1] Acute rat exposure produced brain and organ tissue changes at both tested doses.[19]
Key unknowns include the actual ratio of dopamine-to-SERT activity — which determines whether 3-CMC behaves more like a stimulant or an entactogen in practice. Whether the two mirror-image forms of the molecule produce different effects — as confirmed for mephedrone[20] — remains untested.
Subjective Effects[edit]
3-CMC delivers a stimulant-entactogen hybrid: warm sociability, physical energy, and emotional openness in a rush that tilts more stimulant than MDMA but warmer than pure amphetamine compounds. It peaks quickly and ends sharply, and the craving that follows defines much of the experience.
Community reports place 3-CMC closest to mephedrone in the synthetic cathinone landscape — shorter-acting and slightly less empathogenic.[5] The steep offset and pronounced redosing craving feel more like cocaine than like longer-acting entactogens — a rhythm that punishes unplanned use.
3-CMC first appeared in a Swedish police seizure in September 2014, with no known originating laboratory or clinical purpose.[2] It rose as a successive replacement after mephedrone and 4-CMC were internationally controlled, exploiting a regulatory gap created by its meta-chloro substitution. By 2024, it accounted for over 63% of all new psychoactive substance seizures in Europe and has been increasingly found sold as MDMA.[3][4]
Subjective effects include euphoria, sociability enhancement, physical stimulation, empathy enhancement, and compulsive redosing. The experience is a short-lived stimulant-entactogen hybrid — a rush of warm sociability and energy that drops off sharply, leaving a craving to re-dose that defines much of the compound's character.[5] Anxiety, jaw tension, rapid heartbeat, and difficulty sleeping are common unsought effects.
3-CMC carries high abuse liability, and fatalities where it was the sole substance identified confirm it can be lethal on its own.[6] Its short duration triggers compulsive redosing, escalating cardiovascular strain; cardiac arrhythmias are documented in intoxication cases.[7] No controlled human studies exist — the current understanding rests on animal models, forensic case series, and a single observational metabolism study.[3]
History[edit]
Discovery
3-CMC was not developed for clinical or therapeutic use — no publication records a synthesis date or originating laboratory. It was first identified in September 2014 after Swedish police seized a sample that was reported to the EMCDDA Early Warning System.[2] The compound emerged as a designer drug filling the market gap left after mephedrone was internationally controlled in 2010 and its successor 4-CMC in 2020.[4]
European market dominance
3-CMC's penetration of European drug markets is unprecedented among synthetic cathinones. Seizures surged from 880 kg in 2020 to over 19,400 kg in 2022,[4] and by 2024 the compound represented over 63% of all NPS seized across Europe.[3] Production shifted from China to India after 2015, with the Netherlands intercepting 83% of imports and clandestine laboratories dismantled in the Netherlands and Poland.[4]
Regulatory response
The EU classified 3-CMC as a controlled drug in March 2022 after a risk assessment documented 10 confirmed deaths.[8] In October 2023, the WHO Expert Committee on Drug Dependence recommended placement under Schedule II of the 1971 Convention on Psychotropic Substances,[9][6] endorsed by the EU Council in March 2024.[10] The first confirmed US detection occurred in March 2024 in New York City.[11]
The name clophedrone derives from the chloro-ephedrone structural relationship, though the term sees limited use outside regulatory documents. In European drug markets, 3-CMC is frequently sold under generic labels or disguised as MDMA in pill or crystal form[4] — a substitution pattern that introduces unrecognised exposure among users who believe they are consuming an entirely different substance.
Chemistry[edit]
Structural class
3-CMC belongs to the substituted cathinone family, a subclass of β-keto amphetamines within the broader phenethylamine scaffold. The cathinone skeleton is defined by a carbonyl group at the benzylic position appended to an amphetamine backbone. 3-CMC carries a chlorine atom at the meta (3-) position of the phenyl ring and an N-methyl group on the amine nitrogen, making it a positional isomer of 4-CMC (para-chloro) and a halogenated structural analog of 3-MMC (meta-methyl).
Meta-substitution on the cathinone scaffold has been associated with increased SERT potency relative to DAT potency, compared to para-substituted analogs.[12] This structure-activity relationship positions 3-CMC as potentially more serotonergic than its para-chloro isomer.
Molecular properties
| Molecular formula | C₁₀H₁₂ClNO |
| Molecular weight | 197.66 g/mol |
The molecule consists of a propiophenone core with chlorine at the meta position of the aromatic ring. The α-carbon adjacent to the carbonyl bears a methyl group, and the amine nitrogen carries a single methyl substituent. The β-keto group distinguishes cathinones from their amphetamine parent compounds and is the primary site of metabolic reduction in vivo.
Stereochemistry
The C2 carbon constitutes a chirality centre, producing (R)- and (S)-enantiomers. 3-CMC is sold on the illicit market exclusively as a racemic mixture.[13] Enantioselective metabolism has been confirmed in rats, with both the parent drug and its metabolites showing preferential processing of one enantiomer over the other.[13]
Whether individual enantiomers differ in pharmacological activity has not been tested for 3-CMC. For mephedrone, enantioselective effects on brain chemistry and behaviour are established in rats,[14] suggesting enantiomer-specific pharmacology may be clinically relevant for 3-CMC as well.
Physical properties
No published data characterise the melting point, solubility, or crystal forms of 3-CMC. The compound is distributed as a white to off-white crystalline powder.[6]
3-CMC is notably unstable in biological samples. In whole blood stored at 4°C, the parent compound degrades completely within approximately two months.[15] In a series of 27 postmortem cases involving CMC isomers, only 44% showed detectable parent compound[15] — a fact with direct forensic implications, as death investigations may undercount 3-CMC involvement.
Pharmacology[edit]
Mechanism of action
3-CMC acts as a non-selective monoamine releasing agent at the dopamine, norepinephrine, and serotonin transporters. Rather than blocking reuptake like cocaine, it enters the transporter as a substrate and forces stored monoamines out of the nerve terminal into the synapse, flooding the brain with all three neurotransmitters simultaneously.[16]
Direct evidence comes from studies showing that 3-CMC enhances dopamine and serotonin release in vitro and produces dose-dependent locomotor stimulation in mice — a behavioural signature of monoamine release.[1] No binding affinity values have been published for 3-CMC at any transporter target.
The positional isomer 4-CMC has been directly characterised and functions as a substrate at all three transporters with comparable potency, similar to mephedrone.[17] Structure-activity data for meta-substituted cathinones suggest 3-CMC may exhibit relatively greater serotonergic activity than its para-substituted isomer,[12] though this prediction remains unconfirmed.
Pharmacokinetics
No controlled pharmacokinetic study has reported half-life, bioavailability, or plasma concentration curves for 3-CMC in humans.
The most informative human data come from an observational study of 16 regular users who self-administered 3-CMC orally (100–150 mg) or intranasally (60–80 mg).[3] Nine metabolites were identified, and the route of administration influenced which metabolites appeared — oral dosing produced three exclusive metabolites through first-pass liver metabolism, while a different metabolite accumulated preferentially after insufflation.[3]
The primary metabolic pathway is reduction of the β-keto group, producing dihydro-3-CMC — the dominant metabolite in postmortem samples.[18] Additional pathways include N-demethylation and a combined N-demethylation plus carboxylation route not previously reported for any methcathinone structural analog.[19]
By structural analogy to mephedrone, the liver enzyme CYP2D6 is the probable primary metaboliser.[20] Individuals with genetically low CYP2D6 activity may clear the drug more slowly, increasing exposure and toxicity risk. inferred
Neuroscience[edit]
Where it acts
3-CMC simultaneously increases dopamine, norepinephrine, and serotonin levels across the brain. Dopamine release in the mesolimbic pathway — ventral tegmental area to nucleus accumbens — produces the euphoria and reinforcement that drive continued use.[16] Serotonergic activity, predicted to be relatively pronounced based on the meta-chloro structure,[12] likely underlies the entactogenic warmth and sociability reported by users.[5]
Norepinephrine release drives the sympathomimetic effects — elevated heart rate, blood pressure, and arousal — documented in intoxication cases.[7] At high doses, dopamine flooding impairs sensory gating, as demonstrated by disrupted prepulse inhibition in mice,[7] providing a neurobiological correlate for the psychosis observed in human intoxications.
Why it matters
The incentive salience model explains 3-CMC's compulsive redosing pattern. Dopamine in the nucleus accumbens encodes motivational "wanting" independently of hedonic "liking" — as drug levels fall after 3-CMC's short peak, craving surges before the experience has fully ended, driving repeated dosing.[21]
In vitro studies show delayed toxicity in human neuronal cells, suggesting indirect damage through oxidative stress rather than acute monoamine depletion.[1] Acute rat exposure produced brain tissue changes and oxidative stress markers at both tested doses.[13]
Key unknowns include the actual ratio of dopamine-to-SERT activity, which determines whether 3-CMC is pharmacologically more stimulant-like or entactogen-like. Whether individual enantiomers drive different effects — as confirmed for mephedrone[14] — remains untested.
Subjective Effects[edit]
3-CMC delivers a short-lived stimulant-entactogen hybrid — an initial wave of warm sociability and physical energy that tilts more stimulant than MDMA but carries more emotional openness than pure amphetamine-type compounds. Oral administration tends toward a smoother, more empathogenic arc, while insufflation sharpens the onset into a stimulant-dominant rush. Set and setting strongly modulate which quality dominates — social environments draw out the prosocial character, while solitary use skews toward restless stimulation.
In the synthetic cathinone landscape, community reports position 3-CMC as qualitatively similar to mephedrone but shorter-acting and less entactogenic.[5] The steep offset and pronounced craving at the tail give the experience a redosing rhythm more reminiscent of cocaine than of longer-acting empathogen-stimulants.
Effect Grid
The characteristic stimulant-entactogen profile of 3-CMC is fully expressed. Cognitive euphoria and sociability enhancement are prominent — conversations feel fluid and engaging, with a warm empathetic quality reminiscent of entactogens though less intense than MDMA. Thought acceleration and focus enhancement are noticeable. Disinhibition increases social confidence.
Physical stimulation is clear: elevated heart rate, appetite suppression, pupil dilation, and wakefulness. Bruxism may emerge. Excessive sweating and dry mouth are possible. A pleasant body high and tactile euphoria contribute to the entactogenic character.
The compulsive redosing urge becomes apparent as effects begin to wane — this is a defining feature of 3-CMC at common doses and above. The short duration (3–5 hours oral) amplifies craving during the offset. Sleep will be disrupted for several hours post-experience.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sound sensitivity
Pupil dilation · Wakefulness · Excessive sweating · Insomnia · Muscle tension · Physical fatigue · Restlessness · Body high · Bruxism · Dehydration sensation · Respiratory stimulation · Sexual arousal enhancement · Tactile euphoria · Headache · Nausea · Trembling
Muscle tension · Physical fatigue · Restlessness · Body high · Bruxism · Dehydration sensation · Respiratory stimulation · Sexual arousal enhancement · Tactile euphoria · Headache · Nausea · Trembling
Information processing enhancement · Motivation enhancement · Analysis enhancement
Anxiety · Dysphoria · Emotional enhancement · Empathy enhancement
Disinhibition · Trust enhancement
Timeline
Initial stimulation and mild mood lift begin. A subtle alertness and slight appetite reduction signal absorption.
Euphoria and sociability build steadily. Entactogenic warmth and thought acceleration become apparent as stimulation intensifies.
Full stimulant-entactogen experience with maximal euphoria, sociability enhancement, and physical stimulation. Bruxism, pupil dilation, and appetite suppression are prominent.
Effects diminish with residual stimulation and mild anxiety. Compulsive redosing urge peaks during this phase as subjective effects decline faster than pharmacological activity.
Fatigue, low mood, and residual wakefulness persist. Appetite slowly returns.
⚠ Avoid driving for at least 6 hours after the last dose due to residual stimulation, cognitive impairment, and potential fatigue.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 5 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · mephedrone · MDMA
Toxicity
No lethal dose, therapeutic index, or safe blood concentration has been established for 3-CMC in any species. No controlled human toxicity data exist.
Fatal cases
3-CMC can kill on its own. The WHO Expert Committee documented fatal intoxications where 3-CMC was the sole identified substance,[6] and 10 confirmed deaths were on record at the EU risk assessment in November 2021.[8] A Polish forensic series documented 13 deaths at a single department between 2016 and 2022, with polydrug use present in 82% of all CMC-related fatalities.[12]
No reliable lethal blood concentration exists. Postmortem levels ranged from 10 to 2,800 ng/mL, complicated by rapid degradation of the parent compound in stored samples[12] — meaning death investigations may systematically undercount 3-CMC's role.
Heart and circulation
Cardiovascular toxicity is the primary acute danger. Cardiac arrhythmias and chest pain are documented in human intoxication cases,[7] and computational modelling predicts cardiotoxicity risk across all CMC isomers.[7] safety citation needed No direct cardiac channel studies have been published for 3-CMC.
Organ damage
Acute rat exposure at both tested doses produced measurable damage to brain, liver, and lung tissue, with kidney damage at the higher dose.[19] Oxidative stress markers were elevated across multiple organs.[19] These findings come from single-dose animal studies; their relevance to repeated human use is uncertain.
Temperature effects
3-CMC produces hypothermia in mice[7] — a drop in body temperature, the opposite of the overheating seen with most cathinones and MDMA. No human temperature data exist. Standard cathinone emergency protocols emphasise active cooling, which could be harmful if 3-CMC lowers body temperature in humans.
Detection limitations
Standard hospital drug screens do not reliably identify 3-CMC. It caused false-positive MDMA results in testing and contributed to 17.1% of false-positive MDMA tests in one clinical cohort.[21] Confirmatory laboratory testing is required for accurate identification.
Cytotoxicity
In vitro studies found toxicity to human neuronal cells that emerged and intensified with prolonged exposure, pointing to oxidative stress rather than immediate monoamine-related damage.[1]
Psychological risks
Paranoia, severe agitation, and aggression are documented in human intoxication cases at poison control centres.[7] At the broader cathinone class level, seizures, coma, and excited delirium have been reported.[22]
High-dose 3-CMC disrupted sensory gating in mice[7] — a measure linked to psychosis vulnerability in humans. No data address long-term psychiatric effects or risk in people with pre-existing psychiatric conditions.
Tolerance and dependence
3-CMC dependence is expected to resemble amphetamine-type dependence, and clinical admissions for 3-CMC dependence have been reported.[6] The closely related 3-MMC provides the clearest parallel: its short duration drives intense craving and repeated dosing,[18] and treatment-seeking for problematic 3-MMC use in the Netherlands rose tenfold between 2021 and 2023.[18]
inferred Acute tolerance to euphoria likely develops within a single session, driving redosing. Cross-tolerance with other monoamine releasers — amphetamine, mephedrone, MDMA — is expected but untested.
Drug Interactions
GHB
A fatal case involved 3-CMC combined with GHB in a chemsex setting.[23] Stimulant-driven heart strain combined with GHB's respiratory depression creates unpredictable physiological compromise.[8]
Alcohol
No direct data exist for 3-CMC combined with alcohol. For mephedrone, alcohol significantly increased cardiovascular effects and euphoria while masking sedation.[24] By structural analogy, the combination is expected to increase cardiac risk while reducing awareness of impairment. inferred
MAOIs
As a monoamine releasing agent, combining 3-CMC with monoamine oxidase inhibitors carries class-level risk of dangerous blood pressure spikes and serotonin syndrome — a potentially life-threatening overheating and seizure response. This is a safety-critical contraindication regardless of the absence of substance-specific data. safety citation needed
CYP2D6 inhibitors
If CYP2D6 metabolises 3-CMC as predicted,[17] drugs that block this enzyme — including fluoxetine, paroxetine, bupropion, and quinidine — could slow clearance and raise toxicity. Several are also SSRIs, independently raising serotonin syndrome risk when combined with a serotonin releaser. inferred
Serotonergic agents
Combining 3-CMC with SSRIs, SNRIs, triptans, or other serotonin-active drugs raises the risk of serotonin syndrome. Serotonin syndrome has been documented within the broader cathinone class.[22]
Polydrug patterns
In fatal CMC cases, 82% involved multiple substances — synthetic cannabinoids, synthetic opioids, cocaine, opiates, medications, and/or alcohol.[12]
Contraindications
9 knownHeart conditions (absolute). Cardiac arrhythmias and chest pain are documented in intoxication cases.[7] Pre-existing arrhythmias, coronary artery disease, uncontrolled high blood pressure, or heart muscle disease are absolute contraindications.
MAOI use (absolute). Monoamine releasers combined with MAO inhibitors risk dangerous blood pressure crises and serotonin syndrome. safety citation needed
Kidney impairment (relative). Kidney damage signals were observed in animal studies.[19]
Liver impairment (relative). Liver tissue changes were observed at both doses in rats.[19] Reduced liver function could slow drug clearance and prolong exposure. If CYP2D6 mediates 3-CMC metabolism as predicted, genetically low CYP2D6 activity represents an additional risk factor.[17]
Seizure disorders (relative). Cathinones as a class can lower the seizure threshold.[22]
Pregnancy and breastfeeding (absolute). No reproductive data exist. Stimulants carry class-level risks of restricted blood flow to the placenta and fetal heart rate changes. safety citation needed
Psychiatric conditions (relative). Paranoia and psychosis are documented in intoxication cases.[7] Pre-existing psychotic disorders, bipolar disorder, or severe anxiety disorders increase vulnerability.
Harm Reduction[edit]
Forms & Identification
3-CMC is increasingly sold disguised as MDMA.[4] Standard Marquis and Mecke reagent tests do not reliably distinguish it from other cathinones or from MDMA. Definitive identification requires laboratory analysis — LC-MS/MS or GC-MS.
Drug checking services offering mass spectrometry provide the most reliable confirmation of what a sample actually contains.
Guidelines
- Test every sample before use — 3-CMC is frequently sold as or cut with other substances
- Pre-measure doses; do not redose from the bag
- Set a hard limit on total consumption and number of redoses before the session begins
- Stay hydrated but avoid excessive water intake — electrolyte-containing fluids are preferable
- Eat a light meal beforehand; stimulant appetite suppression makes it easy to neglect nutrition
- Ensure access to a cool, quiet space if overstimulation occurs
- Plan for the comedown: calm environment and next-day recovery time
Set & Setting
Social environments bring out 3-CMC's prosocial qualities. Solitary use tends toward restless overstimulation. The short duration and steep offset mean the compulsive redosing urge can dominate the latter part of any session.
Plan for the redosing impulse before it arrives. Measure a total amount in advance and separate it from remaining supply. A trusted person who understands the compound's short arc can help interrupt the craving-redose cycle.
Aftercare & integration. The comedown typically brings low mood, fatigue, irritability, and difficulty sleeping — a predictable result of temporary monoamine depletion. These effects are not dangerous but can be distressing.
- Sleep: Prioritise rest. Avoid further stimulant use (including caffeine) to allow the sleep cycle to reset.
- Nutrition: Eat nutrient-dense food as soon as appetite returns. Stimulant appetite suppression during the session often means the body is running a caloric deficit.
- Mood: Low mood in the 1–3 days following use is expected and typically self-limiting. Physical activity, social contact, and routine help stabilise mood.
- Warning signs: Persistent low mood beyond 3–4 days, intense craving to use again immediately, or emerging patterns of repeated weekend use warrant honest self-assessment.
Recovery & Support
3-CMC's compulsive redosing pattern means problematic use can develop quickly — treatment-seeking for the closely related 3-MMC increased tenfold in the Netherlands between 2021 and 2023.[18] Professional support is available.
- Addiction services: General stimulant dependence programmes apply; no 3-CMC-specific treatment protocol exists. Mention the specific substance — many clinicians are unfamiliar with synthetic cathinones.
- Peer support: SMART Recovery and similar programmes provide structured frameworks for stimulant use disorders.
- Chemsex-specific support: 3-CMC is increasingly used in chemsex contexts.[8] Specialised chemsex services exist in many European cities and offer non-judgmental support.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency:
Uncomfortable but manageable effects — rapid heartbeat, jaw tension, anxiety — are common. Seek immediate help if any of the following occur:
- Chest pain or pressure
- Seizure or convulsions
- Loss of consciousness or unresponsiveness
- Severe confusion, paranoia, or aggression that cannot be de-escalated
- Body temperature that feels abnormally hot or cold to the touch
- Difficulty breathing
Immediate steps:
- 1. Call emergency services
- 2. Place an unconscious, breathing person in the recovery position (on their side)
- 3. Do not restrain an agitated person unless there is immediate danger to themselves or others
- 4. Monitor breathing and consciousness until help arrives
- 5. Do not induce vomiting
What to tell the dispatcher:
Provide the substance name (3-CMC or "a synthetic cathinone"), the amount taken if known, the time of last dose, the route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
3-CMC is internationally controlled under Schedule II of the 1971 Convention on Psychotropic Substances,[9] following a WHO Expert Committee recommendation in October 2023, endorsed by the EU Council in March 2024.[10]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule II, Convention on Psychotropic Substances (1971) | WHO ECDD 46th meeting recommendation (October 2023)[9] |
| European Union | Controlled as "drug" under EU law since March 2022; Schedule II endorsed via Council Decision 2024/832 | Delegated act amending Framework Decision 2004/757/JHA; 10 deaths reported at time of EU risk assessment (November 2021)[8] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Blanket prohibition on production, supply, and import/export of psychoactive substances (effective May 26, 2016). Not specifically listed as Class A/B/C under the Misuse of Drugs Act 1971. |
| United States | Not explicitly scheduled under the Controlled Substances Act (as of May 2026) | May be subject to the Federal Analogue Act if intended for human consumption. First detected in the US in March 2024.[11] safety citation needed US scheduling status requires verification against current DEA actions. |
| Canada | Not verified | citation needed |
| Australia | Not verified | citation needed |
Analog act considerations
In the United States, where 3-CMC is not explicitly scheduled, the Federal Analogue Act may apply if the compound is deemed substantially similar to a Schedule I or II substance and intended for human consumption. As a methcathinone analog (methcathinone is Schedule I), 3-CMC could be prosecuted under this provision, though enforcement has been inconsistent.[11]
Legal status changes frequently. The information above reflects available data as of May 2026 and is not legal advice. Always verify current scheduling in the relevant jurisdiction.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 5 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · mephedrone · MDMA
Toxicity
No lethal dose, therapeutic index, or safe blood concentration has been established for 3-CMC in any species. No controlled human toxicity data exist.
Fatal cases
3-CMC can kill on its own. The WHO Expert Committee on Drug Dependence documented fatal intoxications where 3-CMC was the sole identified substance.[6] At the time of the EU risk assessment in November 2021, 10 confirmed deaths with 3-CMC exposure had been reported.[8]
A Polish forensic series documented 13 deaths involving 3-CMC at a single department between 2016 and 2022, with polydrug use present in 82% of all CMC-related fatalities.[15] No established lethal blood concentration exists — postmortem levels ranged from 10 to 2,800 ng/mL, complicated by rapid degradation of the parent compound in stored samples.[15]
Heart and circulation
Cardiovascular toxicity is the primary acute danger. Cardiac arrhythmias and chest pain are documented in human intoxication cases,[7] and computational modelling predicts cardiotoxicity risk for all CMC isomers.[7] safety citation needed No direct cardiac channel studies have been published for 3-CMC.
Organ damage
Acute rat exposure at both tested doses produced measurable damage to brain, liver, and lung tissue, with kidney damage at the higher dose.[13] Oxidative stress markers were elevated in brain, lung, and kidney tissue.[13] These findings come from single-dose animal studies; their relevance to repeated human use is uncertain but raises concern.
Temperature effects
3-CMC produces hypothermia in mice,[7] the opposite of the overheating seen with most cathinones and MDMA. No human temperature data exist. This has direct emergency treatment implications: standard cathinone protocols emphasise active cooling, which could be harmful if 3-CMC lowers body temperature in humans.
Detection limitations
Standard hospital drug screens cross-react unreliably with 3-CMC. The compound caused false-positive MDMA results in testing and contributed to 17.1% of false-positive MDMA tests in one clinical cohort.[22] Confirmatory laboratory testing is required for accurate identification.
Cytotoxicity
In vitro studies demonstrated toxicity to human neuronal cells that emerged and intensified with prolonged exposure, suggesting indirect damage through oxidative stress rather than acute monoamine-related mechanisms.[1]
Psychological risks
Psychosis, severe agitation, and aggression are documented in human intoxication cases at poison control centres.[7] At the broader cathinone class level, seizures, coma, and excited delirium syndrome have been reported.[23]
High-dose 3-CMC disrupted sensory gating in mice,[7] a measure linked to psychosis vulnerability in humans. No data address long-term psychiatric effects or specific risk in individuals with pre-existing psychiatric conditions.
Tolerance and dependence
No controlled studies on tolerance or withdrawal exist for 3-CMC. The WHO assessed that 3-CMC dependence is expected to resemble amphetamine-type dependence, and noted that clinical admissions for 3-CMC dependence had been reported.[6]
The structural analog 3-MMC provides the closest dependence model: its short duration drives increased craving and frequent redosing,[21] and treatment-seeking for problematic 3-MMC use in the Netherlands rose tenfold from 33 cases in 2021 to 330 in 2023.[21] 3-CMC users report the same compulsive redosing pattern.[5]
inferred Acute tolerance to euphoric effects likely develops within a single session, driving redosing. Cross-tolerance with other monoamine releasers (amphetamine, mephedrone, MDMA) is expected but untested.
Drug Interactions
GHB
A fatal case involved 3-CMC combined with GHB in a chemsex setting — toxic GHB levels alongside 3-CMC.[24] Stimulant-driven heart strain overlaid on GHB-mediated respiratory depression creates unpredictable physiological compromise. Chemsex contexts, where GHB and stimulant cathinones are frequently co-administered, represent a documented high-risk setting.[8]
Alcohol
No direct data exist for 3-CMC with alcohol. For mephedrone, alcohol co-administration significantly increased cardiovascular effects and euphoria while masking sedation.[25] By structural analogy, 3-CMC plus alcohol is expected to increase cardiac risk while reducing awareness of impairment. inferred
MAOIs
As a monoamine releasing agent, 3-CMC combined with monoamine oxidase inhibitors carries class-level risk of dangerous blood pressure spikes and serotonin syndrome. This is a safety-critical contraindication regardless of the absence of substance-specific data. safety citation needed
CYP2D6 inhibitors
If CYP2D6 metabolises 3-CMC as predicted from mephedrone data,[20] drugs that inhibit this enzyme (fluoxetine, paroxetine, bupropion, quinidine) could slow 3-CMC clearance and increase toxicity. Several of these are SSRIs, which independently raise serotonin syndrome risk when combined with a serotonin releaser. inferred
Serotonergic agents
Combining 3-CMC with SSRIs, SNRIs, triptans, or other serotonin-active drugs raises serotonin syndrome risk. Serotonin syndrome has been documented within the broader cathinone class.[23]
Polydrug patterns
In fatal CMC cases, 82% involved multiple substances — synthetic cannabinoids, synthetic opioids, cocaine, opiates, medications, and/or alcohol.[15]
Contraindications
9 knownHeart conditions (absolute). Cardiac arrhythmias and chest pain are documented in intoxication cases.[7] Pre-existing arrhythmias, coronary artery disease, uncontrolled high blood pressure, or heart muscle disease are absolute contraindications.
MAOI use (absolute). Monoamine releasers combined with MAO inhibitors risk dangerous blood pressure crises and serotonin syndrome. safety citation needed
Kidney impairment (relative). Kidney damage signals were observed in animal studies.[13]
Liver impairment (relative). Liver tissue changes were observed at both doses in rats.[13] Reduced liver function could slow drug clearance and prolong exposure. If CYP2D6 mediates 3-CMC metabolism as predicted, genetically low CYP2D6 activity represents an additional risk factor.[20]
Seizure disorders (relative). Cathinones as a class can lower the seizure threshold.[23]
Pregnancy and breastfeeding (absolute). No reproductive data exist. Stimulants carry class-level risks of restricted blood flow to the placenta and fetal heart rate changes. safety citation needed
Psychiatric conditions (relative). Psychosis is documented in intoxication cases.[7] Pre-existing psychotic disorders, bipolar disorder, or severe anxiety disorders increase vulnerability.
Harm Reduction[edit]
Forms & Identification
3-CMC's greatest identification challenge is that it is increasingly sold disguised as MDMA.[4] Standard Marquis and Mecke reagent tests do not reliably distinguish 3-CMC from other cathinones or from MDMA — definitive identification requires laboratory-grade analysis such as LC-MS/MS or GC-MS.
If reagent testing is the only option available, a combination of multiple reagents may help narrow possibilities, but no single field test can confirm 3-CMC identity. Drug checking services that offer mass spectrometry provide the most reliable verification of what a sample actually contains.
Guidelines
- Test every sample before use — 3-CMC is frequently sold as or cut with other substances
- Pre-measure doses; do not redose from the bag
- Set a hard limit on total consumption and number of redoses before the session begins
- Stay hydrated but avoid excessive water intake — electrolyte-containing fluids are preferable
- Eat a light meal beforehand; stimulant appetite suppression makes it easy to neglect nutrition
- Ensure access to a cool, quiet space if overstimulation occurs
- Plan for the comedown: calm environment and next-day recovery time
Set & Setting
Social environments tend to draw out 3-CMC's prosocial, empathogenic qualities, while solitary use skews toward restless overstimulation. The compound's short duration and steep offset mean the compulsive redosing urge can dominate the latter portion of any session.
Plan for the redosing impulse before it arrives: decide on a total amount in advance and separate it from the remaining supply. Having a trusted person present who understands the compound's short arc can help interrupt the craving-redose cycle.
Aftercare & integration. The comedown from 3-CMC typically involves low mood, fatigue, irritability, and difficulty sleeping — a predictable consequence of temporary monoamine depletion. These effects are not dangerous but can be distressing.
- Sleep: Prioritise rest. Avoid further stimulant use (including caffeine) to allow the sleep cycle to reset.
- Nutrition: Eat nutrient-dense food as soon as appetite returns. Stimulant appetite suppression during the session often means the body is running a caloric deficit.
- Mood: Low mood in the 1–3 days following use is expected and typically self-limiting. Physical activity, social contact, and routine help stabilise mood.
- Warning signs: Persistent low mood beyond 3–4 days, intense craving to use again immediately, or emerging patterns of repeated weekend use warrant honest self-assessment.
Recovery & Support
3-CMC's compulsive redosing pattern means problematic use can develop quickly — treatment-seeking for the closely related 3-MMC increased tenfold in the Netherlands between 2021 and 2023.[21] If use has become difficult to control, professional support is available.
- Addiction services: General stimulant dependence programmes apply; no 3-CMC-specific treatment protocol exists. Mention the specific substance — many clinicians are unfamiliar with synthetic cathinones.
- Peer support: SMART Recovery and similar programmes provide structured frameworks for stimulant use disorders.
- Chemsex-specific support: 3-CMC is increasingly used in chemsex contexts.[8] Specialised chemsex services exist in many European cities and offer non-judgmental support.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency:
Uncomfortable but manageable effects — rapid heartbeat, jaw tension, anxiety — are common. Seek immediate help if any of the following occur:
- Chest pain or pressure
- Seizure or convulsions
- Loss of consciousness or unresponsiveness
- Severe confusion, paranoia, or aggression that cannot be de-escalated
- Body temperature that feels abnormally hot or cold to the touch
- Difficulty breathing
Immediate steps:
- 1. Call emergency services
- 2. Place an unconscious, breathing person in the recovery position (on their side)
- 3. Do not restrain an agitated person unless there is immediate danger to themselves or others
- 4. Monitor breathing and consciousness until help arrives
- 5. Do not induce vomiting
What to tell the dispatcher:
Provide the substance name (3-CMC or "a synthetic cathinone"), the amount taken if known, the time of last dose, the route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
3-CMC is internationally controlled under Schedule II of the 1971 Convention on Psychotropic Substances, following the recommendation of the WHO Expert Committee on Drug Dependence in October 2023.[9] The EU endorsed this placement through Council Decision 2024/832 of March 4, 2024.[10] Within the EU, 3-CMC was already controlled as a "drug" under EU law from March 18, 2022, via a delegated act amending Council Framework Decision 2004/757/JHA.[8]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule II, Convention on Psychotropic Substances (1971) | WHO ECDD 46th meeting recommendation (October 2023)[9] |
| European Union | Controlled as "drug" under EU law since March 2022; Schedule II endorsed via Council Decision 2024/832 | Delegated act amending Framework Decision 2004/757/JHA; 10 deaths reported at time of EU risk assessment (November 2021)[8] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Blanket prohibition on production, supply, and import/export of psychoactive substances (effective May 26, 2016). Not specifically listed as Class A/B/C under the Misuse of Drugs Act 1971. |
| United States | Not explicitly scheduled under the Controlled Substances Act (as of May 2026) | May be subject to the Federal Analogue Act if intended for human consumption. First detected in the US in March 2024.[11] safety citation needed US scheduling status requires verification against current DEA actions. |
| Canada | Not verified | citation needed |
| Australia | Not verified | citation needed |
Analog act considerations
In the United States, where 3-CMC is not explicitly scheduled, the Federal Analogue Act (21 U.S.C. § 813) may apply if the compound is deemed substantially similar in structure or pharmacological effect to a Schedule I or II controlled substance and is intended for human consumption. As a methcathinone analog (methcathinone is Schedule I), 3-CMC could be prosecuted under this provision, though analogue enforcement for synthetic cathinones has been inconsistent in practice.[11]
Frequently asked questions
What is 3-CMC?
3-CMC is a synthetic substituted cathinone and non-selective monoamine releasing agent producing stimulant and mild entactogenic effects. First identified in Europe in 2014, it became the continent's most seized new psychoactive substance by 2024 and is internationally controlled under Schedule II.
How long does 3-CMC last?
Total duration by route of administration — Oral: 3 – 5 hours; Insufflated: 2 – 4 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 3-CMC?
Psychedex publishes a dosage table for 3-CMC on this page covering these routes of administration: oral, insufflated. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 3-CMC?
The highest-severity documented interactions for 3-CMC: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Antipsychotics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 3-CMC addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 3-CMC: tolerance builds moderate; full reset takes 5 days; cross-tolerance develops with amphetamine, mephedrone, MDMA, 3-MMC, 4-CMC, methcathinone. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcdWojcieszak J, Kuczyńska K, Zawilska JB (2020) Four Synthetic Cathinones: 3-Chloromethcathinone, 4-Chloromethcathinone, 4-Fluoro-α-Pyrrolidinopentiophenone, and 4-Methoxy-α-Pyrrolidinopentiophenone Produce Changes in the Spontaneous Locomotor Activity and Motor Performance in Mice with Varied Profiles. — Neurotoxicity Research doi:10.1007/s12640-020-00227-8
- [2]
- [3] ^abcdeDi Trana A, La Maida N, Graziano S, Pichini S, Hladun O, Poyatos L, Ventura M, Papaseit E, Farré M, Perez-Maña C (2026) The Influence of Routes of Administration on 3-chloromethcathinone Urinary Biomarkers Disposition: Preliminary In Vivo Study of Unknown Metabolites Profiling on Healthy Volunteers. — The AAPS Journal doi:10.1208/s12248-025-01200-z
- [4]
- [5]
- [6]
references
- [1] ^abcdWojcieszak J, Kuczyńska K, Zawilska JB (2020) Four Synthetic Cathinones: 3-Chloromethcathinone, 4-Chloromethcathinone, 4-Fluoro-α-Pyrrolidinopentiophenone, and 4-Methoxy-α-Pyrrolidinopentiophenone Produce Changes in the Spontaneous Locomotor Activity and Motor Performance in Mice with Varied Profiles. — Neurotoxicity Research doi:10.1007/s12640-020-00227-8
- [2]
- [3] ^abcdeDi Trana A, La Maida N, Graziano S, Pichini S, Hladun O, Poyatos L, Ventura M, Papaseit E, Farré M, Perez-Maña C (2026) The Influence of Routes of Administration on 3-chloromethcathinone Urinary Biomarkers Disposition: Preliminary In Vivo Study of Unknown Metabolites Profiling on Healthy Volunteers. — The AAPS Journal doi:10.1208/s12248-025-01200-z
- [4]
- [5]
- [6]